DCCR (diazoxide choline) extended-release tablets
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SH2B1 Deficiency Obesity
Conditions
SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant), SIM1 Deficiency Obesity
Trial Timeline
Jan 1, 2023 → Mar 1, 2024
NCT ID
NCT05532020About DCCR (diazoxide choline) extended-release tablets
DCCR (diazoxide choline) extended-release tablets is a phase 2 stage product being developed by Soleno Therapeutics for SH2B1 Deficiency Obesity. The current trial status is unknown. This product is registered under clinical trial identifier NCT05532020. Target conditions include SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant), SIM1 Deficiency Obesity.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05532020 | Phase 2 | UNKNOWN |